Literature DB >> 16300039

Medications for treating alcohol dependence.

Steven H Williams1.   

Abstract

Medications for treating alcohol dependence primarily have been adjunctive interventions, and only three medications--disulfiram, naltrexone, and acamprosate--are approved for this indication by the U.S. Food and Drug Administration. Disulfiram, an aversive agent that has been used for more than 40 years, has significant adverse effects and compliance difficulties with no clear evidence that it increases abstinence rates, decreases relapse rates, or reduces cravings. In contrast, naltrexone, an anticraving agent, reduces relapse rates and cravings and increases abstinence rates. Acamprosate also reduces relapse rates and increases abstinence rates. Serotonergic and anticonvulsant agents promise to play more of a role in the treatment of alcohol dependence. Although not approved by the U.S. Food and Drug Administration for this indication, the anticonvulsant topiramate and several serotonergic agents (e.g., fluoxetine, ondansetron) have been shown in recent studies to increase abstinence rates and decrease drinking.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16300039

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  34 in total

1.  An eight-week, open-label, prospective case series of acamprosate calcium as monotherapy for patients with comorbid anxiety symptoms and alcohol misuse: an evaluation for alcohol sobriety and anxiolysis.

Authors:  Thomas L Schwartz; Mark Chilton; Alka Aneja
Journal:  Psychiatry (Edgmont)       Date:  2007-04

2.  Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking.

Authors:  Jennifer A Rinker; Diana B Fulmer; Heather Trantham-Davidson; Maren L Smith; Robert W Williams; Marcelo F Lopez; Patrick K Randall; L Judson Chandler; Michael F Miles; Howard C Becker; Patrick J Mulholland
Journal:  Alcohol       Date:  2016-06-27       Impact factor: 2.405

3.  Accumbens neurochemical adaptations produced by binge-like alcohol consumption.

Authors:  Karen K Szumlinski; Mahdi E Diab; Raquel Friedman; Liezl M Henze; Kevin D Lominac; M Scott Bowers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

4.  Screening for alcohol problems: an epidemiological perspective and implications for primary care.

Authors:  Richard A Grucza; Thomas R Przybeck; C Robert Cloninger
Journal:  Mo Med       Date:  2008 Jan-Feb

Review 5.  Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.

Authors:  Jing Liang; Richard W Olsen
Journal:  Acta Pharmacol Sin       Date:  2014-08       Impact factor: 6.150

6.  A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm.

Authors:  David M Penetar; Lindsay H Toto; David Y-W Lee; Scott E Lukas
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

7.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

Review 8.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 9.  Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment.

Authors:  Christian Jacob
Journal:  J Neural Transm (Vienna)       Date:  2012-08-19       Impact factor: 3.575

Review 10.  Emerging pharmacotherapy of tinnitus.

Authors:  Berthold Langguth; Richard Salvi; Ana Belén Elgoyhen
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.